PD-L1 IHC — Dako 22C3 pharmDx clone
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-PDL1-22C3-CLONE |
|---|---|
| Type | Biomarker |
| Aliases | 22C3Dako 22C3PD-L1 22C3 (Dako pharmDx)PD-L1 22C3 pharmDxPD-L1 ІГХ — клон Dako 22C3 pharmDx |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-KEYNOTE-024-RECK-2016 SRC-KEYNOTE-189-GANDHI-2018 SRC-KEYNOTE-407-PAZ-ARES-2018 SRC-NCCN-NSCLC-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC with Dako 22C3 pharmDx companion diagnostic on Autostainer Link 48. Scoring depends on tumor type: - NSCLC: TPS (Tumor Proportion Score, % membranous tumor-cell staining) - Gastric/GEJ, esophageal, cervical, urothelial, H&N, TNBC: CPS (Combined Positive Score, including tumor + lymphocytes + macrophages) UnitsTPS % OR CPS score (assay-specific cut-points by indication) Typical range
|
| Related biomarkers | BIO-PDL1-EXPRESSION BIO-PDL1-TPS BIO-PDL1-CPS |
Notes
Companion-diagnostic clone-specific entity. Distinct from BIO-PDL1-TPS / BIO-PDL1-CPS (scoring conventions) because the assay clone matters: pembrolizumab indications require 22C3 specifically per FDA labeling, and 22C3 vs SP142 are NOT interchangeable on immune-cell-weighted scoring. Used by render layer to surface assay-validity warnings when a patient profile reports PD-L1 testing with a non-22C3 clone for a pembrolizumab-routed indication.
Used By
Indications
IND-NSCLC-PDL1-22C3-PEMBRO-CLONE-SPECIFIC- IND-NSCLC-PDL1-22C3-PEMBRO-CLONE-SPECIFIC